Glut-1 expression in proliferative endometrium, endometrial hyperplasia, endometrial adenocarcinoma and the relationship between glut-1 expression and prognostic parameters in endometrial adenocarcinoma

GLUT 1 expression is a supportive mean in predicting prognosis and survival estimates of endometrial carcinoma

“…3). In agreement with the majority of literature data, our results were capable statically to show increased cytoplasmic and/or membranous expression of GLUT1 in ECs compared to normal endometrium [11][12][13][14][15][16][17][18][19][20][21][22]. Decreased GLUT1 expression in normal endometrium as well as its weak expression in non-cancerous lesions and overexpression in endometrial cancer suggests that this molecule might be involved in endometrial carcinogenesis as the findings of this study and others [12,14] showed significant association with tumor stage.…”

“…increasing grade and stage, is statistically significant [12,14]. Goldman et al (2006) [21] and later Canpolat et al (2016) [13] reported that among clinical characteristics, only grade was found to be significantly correlated to GLUT1 expression. According to Xiong et al [16], the expression of GLUT1 can be used to distinguish between benign endometrial lesions and endometrial cancer but has no prognostic value in women with this malignancy.…”

“…In endometrial neoplasms, nevertheless, many studies [11][12][13][14][15][16][17][18][19][20][21][22] tried to find a comparable association and verify that the IHC GLUT1 phenotype could be utilized as a diagnostic and prognostic tissue marker, but the findings were inconsistent (Tab. 3).…”

“…Many recent studies associated GLUT1 expression with increased malignant potential, invasiveness, diagnosis, prognosis and survival in different neoplasms, including prostate, breast, colorectal, ovarian, lung, hepatic, pancreatic, esophageal and cervical carcinomas [8][9][10]. However, in endometrial cancer, many studies attempted to find similar association and prove that GLUT1 phenotype could be utilized as a diagnostic and prognostic tissue marker, but the findings were inconsistent and need further confirmation [11][12][13][14][15][16][17][18][19][20][21][22]. Therefore, this manuscript will describe the immunohistochemistry phenotype of GLUT1 in a panel of endometrial carcinomas compared to normal tissues, and analyse its relationship with clinicopathological features, to determine its clinical value and its role in endometrial cancer.…”

The Anti-cancer Effect of Olea europaea L. Products: a Review

“…Human malignancies are associated with elevated glucose uptake and enhanced expression of several GLUT isoforms [ 44 ]. This explains how normal cells can reverse the rounding effects of oleuropein treatment, as normal cells have low expression of GLUTs [ 45 , 46 ].…”